CTI Life Sciences led a $115m Series C round in Glycomine.

CTI Life Sciences, a venture capital investment firm, led a $115m Series C round in Glycomine, a biopharmaceutical company, with participation from Novo Holdings, Sanofi Ventures, Abingworth Management, RiverVest Venture Partners, Sanderling Ventures, Chiesi Ventures, Remiges Ventures, and Asahi Kasei Ventures. “We are excited to partner with our new investors who have strong track records in rare diseases, and for the continued support from our existing investors. This financing will enable us to advance GLM101 into a randomized, placebo-controlled trial later this year—an important step toward bringing the first disease-modifying therapeutic to patients with PMM2-CDG,” Steve Axon, Glycomine CEO.